Literature DB >> 15899984

Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions.

Thomas Baltus1, Philipp von Hundelshausen, Sebastian F Mause, Wolfgang Buhre, Rolf Rossaint, Christian Weber.   

Abstract

Platelet-derived chemokines, such as regulated on activation, normal T expressed and secreted (RANTES; CC chemokine ligand 5), platelet factor 4 [PF4; CXC chemokine ligand 4 (CXCL4)], and epithelial neutrophil-activating protein 78 (ENA-78; CXCL5), or precursors, such as beta-thromboglobulin, which can be processed to neutrophil-activating protein-2 (NAP-2; CXCL7), may play an important role in monocyte recruitment during atherogenesis. Platelets can deposit chemokines on inflamed endothelium; however, little is known about differential or additive effects of platelet chemokines on monocyte arrest. Here, we demonstrate that preincubation of activated human microvascular endothelial cells (HMVECs) with RANTES, PF4, or NAP-2 but not ENA-78 dose-dependently increased surface immobilization and subsequent monocyte arrest in flow. RANTES was the most potent and efficient arrest chemokine. Pretreatment of HMVECs with beta-thromboglobulin enhanced monocyte arrest in the presence of cathepsin G generating NAP-2. Combined pretreatment of HMVECs with RANTES and PF4 at suboptimal concentrations synergistically increased arrest, and preincubation with chondroitinase ABC abrogated RANTES- and PF4-induced monocyte arrest. This was associated with reduced expression of chondroitin sulfate, RANTES, and PF4 on the HMVEC surface. Perfusion of HMVECs with platelets known to deposit RANTES and PF4 on the endothelial surface enhanced monocyte arrest, which was inhibited by Met-RANTES, chondroitinase, or a blocking antibody to PF4 but not to ENA-78. The relevance of platelet-derived chemokines was confirmed in adhesion assays with activated whole blood, where Met-RANTES and to a lesser extent, antibodies to PF4 and NAP-2 inhibited arrest of CD14-positive monocytes. Thus, multiple platelet-derived chemokines and processable precursors, which can be presented by specific endothelial proteoglycans, may contribute and cooperate differentially to induce monocyte recruitment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899984     DOI: 10.1189/jlb.0305141

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  24 in total

Review 1.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

2.  Platelets in early antibody-mediated rejection of renal transplants.

Authors:  Hsiao-Hsuan Kuo; Ran Fan; Nina Dvorina; Andres Chiesa-Vottero; William M Baldwin
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

3.  Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection.

Authors:  Guanfang Shi; David J Field; Kyung-ae Ko; Sara Ture; Kalyan Srivastava; Scott Levy; M Anna Kowalska; Mortimer Poncz; Deborah J Fowell; Craig N Morrell
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

4.  Disruption of platelet-derived chemokine heteromers prevents neutrophil extravasation in acute lung injury.

Authors:  Jochen Grommes; Jean-Eric Alard; Maik Drechsler; Sarawuth Wantha; Matthias Mörgelin; Wolfgang M Kuebler; Michael Jacobs; Philipp von Hundelshausen; Philipp Markart; Malgorzata Wygrecka; Klaus T Preissner; Tilman M Hackeng; Rory R Koenen; Christian Weber; Oliver Soehnlein
Journal:  Am J Respir Crit Care Med       Date:  2012-01-12       Impact factor: 21.405

Review 5.  Platelets and Their Interactions with Other Immune Cells.

Authors:  Fong W Lam; K Vinod Vijayan; Rolando E Rumbaut
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

Review 6.  Therapeutic targeting of chemokine interactions in atherosclerosis.

Authors:  Rory R Koenen; Christian Weber
Journal:  Nat Rev Drug Discov       Date:  2010-02       Impact factor: 84.694

Review 7.  CXCR4: a virus's best friend?

Authors:  Kathleen L Arnolds; Juliet V Spencer
Journal:  Infect Genet Evol       Date:  2014-05-02       Impact factor: 3.342

Review 8.  Mechanisms of antibody-mediated acute and chronic rejection of kidney allografts.

Authors:  William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  Curr Opin Organ Transplant       Date:  2016-02       Impact factor: 2.640

Review 9.  Role of platelets in neuroinflammation: a wide-angle perspective.

Authors:  Lawrence L Horstman; Wenche Jy; Yeon S Ahn; Robert Zivadinov; Amir H Maghzi; Masoud Etemadifar; J Steven Alexander; Alireza Minagar
Journal:  J Neuroinflammation       Date:  2010-02-03       Impact factor: 8.322

10.  Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity.

Authors:  M Gziut; H J MacGregor; T G Nevell; T Mason; D Laight; J K Shute
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.